Form 8-K - Current report:
SEC Accession No. 0001213900-17-007992
Filing Date
2017-07-28
Accepted
2017-07-28 09:17:05
Documents
9
Period of Report
2017-07-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k072817_actiniumpharma.htm 8-K 43950
2 UNDERWRITING AGREEMENT, DATED AS OF JULY 28, 2017, BY AND BETWEEN ACTINIUM PHARM f8k072817ex1i_actinium.htm EX-1.1 196877
3 OPINION OF THE MATT LAW FIRM, PLLC. f8k072817ex5i_actinium.htm EX-5.1 11023
4 FORM OF WARRANT f8k072817ex10i_actinium.htm EX-10.1 131603
5 PRESS RELEASE ISSUED BY ACTINIUM PHARMACEUTICALS, INC. DATED JULY 27, 2017 f8k072817ex99i_actinium.htm EX-99.1 10944
6 PRESS RELEASE ISSUED BY ACTINIUM PHARMACEUTICALS, INC. DATED JULY 28, 2017. f8k072817ex99ii_actinium.htm EX-99.2 14696
7 GRAPHIC ex99i_001.jpg GRAPHIC 48668
8 GRAPHIC ex99ii_001.jpg GRAPHIC 40953
9 GRAPHIC ex5i.jpg GRAPHIC 13790
  Complete submission text file 0001213900-17-007992.txt   553163
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 17988027
SIC: 2834 Pharmaceutical Preparations